Tetraphase Pharma announces submission and validation of IV Eravacycline MAA by EMA
Tetraphase Pharmaceuticals announced the MAA for IV eravacycline for the treatment of complicated intra-abdominal infections has been submitted and was validated by the EMA. Eravacycline is a novel, fully-synthetic fluorocycline antibiotic being developed for the treatment of serious infections. August 17, 2017